top of page
istockphoto-1408664308-final copy.jpg

Creating a world without cancer

Defeating cancer using virus biology

We are developing next-generation oncolytic virus immunotherapies designed to selectively destroy cancer cells while directing the body's natural defenses against cancer.

Our proprietary patented platform leverages a novel modified vaccinia virus (VACV) designed to exploit cancer cells' deficiencies in cell death programs, delivering exceptional selectivity and maximum destruction of cancer cells.

Be a part of the impact.

A new era for Oncolytic Virus therapy

WHY

Transforming lives

Envision a future where cancer is no longer a devastating threat, but a manageable condition without adverse events. Our oncolytic virus immunotherapy platform has the potential to transform the cancer treatment landscape and offer new hope to millions of patients.

“Our OV platform is derived from exploiting infection biology.”

– Prof. Ian Mohr, NYU School of Medicine

Current cancer treatments like radiation, chemotherapy, and surgery often lack precision, affecting both healthy and cancerous cells, leading to significant side effects and limited effectiveness in advanced or resistant cancers.

Omios OV therapy addresses the limitations of current therapies by selectively targeting metastases, and offering improved tolerability, resistance-free treatment, and lasting results to prevent relapse.

Help lead the way in driving breakthroughs

Cancer's complexity demands sophisticated therapies”

– Aldo Pourchet Founder and CEO

HOW

Revolutionizing cancer treatment by harnessing the power of viruses

Our innovative approach is based on a deep understanding of the complex interplay between viruses and human cells, both healthy and cancerous. We have engineered a novel vaccinia virus that offers a safe, effective, and versatile platform for treating a wide range of solid tumors.

How it works

A new way to design
oncolytic viruses

A paradigm shift

While previous approaches relied on attenuation for safety and to the detriment of efficacy, we've engineered a more selective solution. Our modified vaccinia viruses are designed to replicate only in the presence of specific cancer mutations in cell death programs; a hallmark of cancer cells.

This innovative approach enhances the viruses' ability to selectively target and destroy cancer cells while stimulating a potent anti-tumor immune response. As the first oncolytic virus platform with a built-in biomarker, Omios Bio provides a solid foundation for building the next generation of cancer immunotherapy.

Be a catalyst for the future of cancer research.

A technological revolution patented by pioneers

Vaccinia virus

Historically a benign virus used to create the first vaccine to eradicate smallpox, the only viral disease eradicated to date.

Omios' modified vaccinia virus

Engineered for safety and maximum efficacy against cancer. By deleting specific viral genes (e.g E3L, D10), we've generated safe vectors with exceptional cancer selectivity. We've also added therapeutic genes to further increase cancer killing activity and boost the anti-cancer immune response.

Omios modified illust.png

Here’s how it works

Technology Platform
1.png

1.

Omios Oncolytic Virus (OV) platform leverages a biomarker to treat patients sooner and better

2.png

2.

Systemic intravenous delivery

3.png

3.

Selectively target the tumor 

4.png

4.

Maximum lytic activity for a durable impact on cancer

5.png

5.

Combination with standard of care

6.png

6.

No added toxicity

Be a catalyst for the future of cancer research.

THE PLAN

Our path forward

We are developing life-changing cancer therapies that are accessible to patients worldwide at any stage of their journey.

We began our journey focusing on breast, liver, and colon cancers. Over 5.3 million patients are diagnosed globally with these three cancers each year. It is projected that the global economic burden between 2020–2050 from these 3 cancers is an estimated 6.6 trillion dollars in treatment.

shutterstock_2165961755_cc.jpg

Our technology pipeline focuses on developing safe and selective oncolytic vaccinia viruses that can combine with standard of care.

Our 3 programs

Oncolytic Virus therapy

Uses Oncolytic Virus platform based on a newly patented vaccinia virus.

Vaccine platform for cancer + infectious diseases

Uses a modified vaccinia virus to create vaccines for cancer and infectious diseases.

Gene Delivery platform

Uses a modified vaccinia virus for systemic gene delivery to treat solid tumors.

Our program
Program.jpg

Invest in promising technology.

The team

THE TEAM

Over 80 years of expertise in Oncolytic Virus development and manufacturing

The team

The Omios founding team brings together a unique blend of deep scientific expertise in oncolytic virotherapy, successful biotech entrepreneurship, and proven business acumen. We are dedicated to applying the highest standards of scientific rigor to bring our therapies to patients.

team member copy-Aldo2.jpg

Aldo Pourchet DVM, PhD

Founder and Chief Executive Officer of Omios Biologics

Dr. Pourchet developed the oncolytic virus T-Stealth when a postdoctoral fellow in the laboratory of Prof. Ian Mohr at NYU. This new immunotherapy, further developed by BeneVir Biopharm Inc.,  was acquired by Janssen...

team member copy-Ian.jpg

Ian Mohr, PhD

Scientific Co-founder

Chair, Scientific Advisory Board

Ian Mohr is a Professor of Microbiology at NYU School of Medicine. Professor Mohr developed the genetic backbone of the first oncolytic virus approved in the US and Europe, T-Vec/Imlygic, T-Vec/Imlygic, commercialized...

team member copy-Ed.jpg

Prof. Edward Mocarski, PhD

Acting Omios Chief Scientific Officer

Professor Mocarski is a world renown virologist who discovered mechanisms of inflammatory cell death programs that are at the core of our technology to control vaccinia replicative cycle, harness innate immunity...

team member copy-Bruno.jpg

Bruno Larida MSc, MBA

Omios Chief Business Officer

Bruno is a seasoned biomedical executive with over 25 years of international experience in subsidiary creation, marketing, manufacturing, and R&D leadership, particularly in immunology, infectious disease, and oncology...

Omios Bio Advisors

Our advisors are world-renowned virologists, immunologists, and experienced biotech executives with a proven track record in oncolytic virus development, regulatory affairs, and successful commercialization of cancer therapies. They provide critical guidance in poxvirus engineering, clinical trial design, GMP manufacturing, and business strategy, ensuring the successful translation of Omios's cutting-edge science into impactful cancer treatments.

team member copy-Julie.jpg

Julie M Cherrington, PhD

Biotechnology Executive, Board Chair/Member, Advisor

Formerly President, CEO and board member of QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics.

team member copy-Leonard.jpg

Leonard Post, PhD

Biotech industry advisor and board member. Former CSO of Vivace, BioMarin, Onyx.

team member copy-Laurent.jpg

Laurent Coscoy, PhD

Professor of Immunology and Molecular Medicine 

UC Berkeley Department of Molecular & Cell Biology

team member copy-Brain.jpg

Brian Ruffell, PhD

Department of Immunology
H. Lee Moffitt Cancer Center

team member copy-Laurence.jpg

Laurence Nore, MBA

Executive Vice-President, Business Development and operation at IgGenix

Help us change the future of cancer

Creativity and complexity drive innovative therapies

News & Events

News events

Contact us

We are committed to advancing the field of oncolytic virus immunotherapy through rigorous research, innovative engineering, and collaborative partnerships.

Select one:
Investor
Provider
Patient
Contact Us
bottom of page